Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $392.00

Shares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twelve analysts that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $392.00.

Several analysts have recently weighed in on the company. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a report on Monday, April 21st. Morgan Stanley lifted their price target on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. cut their target price on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st.

Insider Activity at United Therapeutics

In related news, Director Raymond Dwek sold 4,000 shares of the stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the transaction, the director now directly owns 1,750 shares of the company's stock, valued at $497,962.50. This represents a 69.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,500 shares of company stock worth $16,923,950 in the last three months. Insiders own 10.30% of the company's stock.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of UTHR. Signaturefd LLC grew its holdings in United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after acquiring an additional 30 shares during the period. Parallel Advisors LLC boosted its position in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 30 shares in the last quarter. Anchor Investment Management LLC grew its stake in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the period. Great Lakes Advisors LLC increased its holdings in shares of United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after purchasing an additional 33 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

UTHR stock traded down $4.03 during midday trading on Thursday, reaching $316.34. 886,326 shares of the company were exchanged, compared to its average volume of 443,403. The company has a market cap of $14.27 billion, a price-to-earnings ratio of 13.89, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $417.82. The stock's 50-day simple moving average is $299.49 and its 200 day simple moving average is $335.31.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same period in the previous year, the company earned $6.17 earnings per share. United Therapeutics's quarterly revenue was up 17.2% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.